Nexien BioPharma, Inc. (OTCMKTS: NXEN) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On December 5, 2018, Nexien BioPharma, Inc. sent a letter to its stockholders describing its latest developments. A copy of the letter is included as Exhibit 20.1. This Form 8-K and the information included as exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Registrant or any of its affiliates.
Item 9.01 Financial Statements and Exhibits.
NEXIEN BIOPHARMA, INC. ExhibitEX-20.1 2 ex20-1.htm 4340 E Kentucky Ave Suite 206 Glendale,…To view the full exhibit click here
